Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course

被引:60
作者
Beaumont, T
van Nuenen, A
Broersen, S
Blattner, WA
Lukashov, VV
Schuitemaker, H
机构
[1] CLB Sanquin, Dept Clin Viroimmunol, NL-1066 CX Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Expt & Clin Immunol Lab, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Human Retrovirus Lab, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA
关键词
D O I
10.1128/JVI.75.5.2246-2252.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The role of humoral immunity in controlling human immunodeficiency virus type 1 (HIV-1) is still controversial. The resistance of primary HIV-1 variants to neutralization by antibodies, sera from HIV-1-infected patients, and soluble CD4 protein has been suggested to be a prerequisite for the virus to establish persistence in vivo. To further test this hypothesis, we studied the neutralization sensitivity of two IIIB/LAV variants that were isolated from a laboratory worker who accidentally was infected with the T-cell-line-adapted neutralization-sensitive IIIB isolate. Compared to the original virus in the inoculum, the reisolated viruses showed an increased resistance to neutralization over time. The ratio of nonsynonymous to synonymous nucleotide substitutions in the envelope gene pointed to strong positive selection. The emergence of neutralization-resistant HIV preceded disease development in this laboratory worker. Our results imply that the neutralization resistance of primary HIV may indeed be considered an escape mechanism from humoral immune control.
引用
收藏
页码:2246 / 2252
页数:7
相关论文
共 66 条
  • [41] Parren PWHI, 1999, AIDS, V13, pS137
  • [42] Role of gp41 glycosylation sites in the biological activity of human immunodeficiency virus type 1 envelope glycoprotein
    Perrin, C
    Fenouillet, E
    Jones, IM
    [J]. VIROLOGY, 1998, 242 (02) : 338 - 345
  • [43] Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection
    Pilgrim, AK
    Pantaleo, G
    Cohen, OJ
    Fink, LM
    Zhou, JY
    Zhou, JT
    Bolognesi, DP
    Fauci, AS
    Montefiori, DC
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (04) : 924 - 932
  • [44] DIFFERENCES IN THE ANTIBODY-RESPONSE TO HUMAN IMMUNODEFICIENCY VIRUS-1 ENVELOPE GLYCOPROTEIN (GP160) IN INFECTED LABORATORY WORKERS AND VACCINEES
    PINCUS, SH
    MESSER, KG
    SCHWARTZ, DH
    LEWIS, GK
    GRAHAM, BS
    BLATTNER, WA
    FISHER, G
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (05) : 1987 - 1996
  • [45] TEMPORAL ANALYSIS OF THE ANTIBODY-RESPONSE TO HIV ENVELOPE PROTEIN IN HIV-INFECTED LABORATORY WORKERS
    PINCUS, SH
    MESSER, KG
    NARA, PL
    BLATTNER, WA
    COLCLOUGH, G
    REITZ, M
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (06) : 2505 - 2513
  • [46] Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo
    Poignard, P
    Sabbe, R
    Picchio, GR
    Wang, M
    Gulizia, RJ
    Katinger, H
    Parren, PWHI
    Mosier, DE
    Burtons, DR
    [J]. IMMUNITY, 1999, 10 (04) : 431 - 438
  • [47] Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: A predominant gag-specific response is associated with nonprogressive infection
    Pontesilli, O
    Klein, MR
    Kerkhof-Garde, SR
    Pakker, NG
    de Wolf, F
    Schuitemaker, H
    Miedema, F
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (04) : 1008 - 1018
  • [48] POSNER MR, 1991, J IMMUNOL, V146, P4325
  • [49] VIRAL VARIABILITY AND SERUM ANTIBODY-RESPONSE IN A LABORATORY WORKER INFECTED WITH HIV TYPE-1 (HTLV TYPE IIIB)
    REITZ, MS
    HALL, L
    ROBERTGUROFF, M
    LAUTENBERGER, J
    HAHN, BM
    SHAW, GM
    KONG, LI
    WEISS, SH
    WATERS, D
    GALLO, RC
    BLATTNER, W
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (09) : 1143 - 1155
  • [50] NEUTRALIZATION SENSITIVITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IS DETERMINED IN PART BY THE CELL IN WHICH THE VIRUS IS PROPAGATED
    SAWYER, LSW
    WRIN, MT
    CRAWFORDMIKSZA, L
    POTTS, B
    WU, YM
    WEBER, PA
    ALFONSO, RD
    HANSON, CV
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (03) : 1342 - 1349